Rankings
▼
Calendar
TBPH Q4 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena
TBPH
Theravance Biopharma, Inc.
$716M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
+6.8% YoY
Gross Profit
$19M
100.0% margin
Operating Income
-$9M
-49.1% margin
Net Income
-$16M
-82.8% margin
EPS (Diluted)
$-0.31
QoQ Revenue Growth
+11.2%
Cash Flow
Operating Cash Flow
-$902,000
Free Cash Flow
-$1M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$354M
Total Liabilities
$179M
Stockholders' Equity
$176M
Cash & Equivalents
$38M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$18M
+6.8%
Gross Profit
$19M
$9M
+102.7%
Operating Income
-$9M
-$6M
-47.4%
Net Income
-$16M
-$9M
-82.5%
Revenue Segments
YUPELRI Monotherapy
$23M
100%
← FY 2024
All Quarters
Q1 2025 →